Introduction Epilepsy, a prevalent neurodegenerative disorder, profoundly impacts the
physical and mental well-being of millions globally. Historically, antiseizure drugs (ASDs) …

Background Nanocarriers have been proposed as a solution for drug-resistant epilepsy.
Methods A systematic review of animal and in vitro studies was conducted to evaluate the …

This study focuses on the design, characterization, and optimization of nanostructured lipid
carriers (NLCs) loaded with docetaxel for the treatment of skin cancer. Employing a …

Chagas disease is a neglected endemic disease prevalent in Latin American countries,
affecting around 8 million people. The first-line treatment, benznidazole (BNZ), is effective in …

Epilepsy, a prevalent and frequently incapacitating neurological disease affecting over 50
million people worldwide, exhibits substantial treatment challenges, particularly in one-third …

Epilepsy is a disease of the central nervous system that is characterized by recurring
seizures. Because of the complex nature of the brain's protective barriers and the limitations …

Despite the continuous expansion of the available pharmacological options for the treatment
of epilepsies and remarkable advances in understanding their pathophysiology, the …

The growth of nanostructured lipid carriers for brain targeting shows a promising strategy for
escalating the therapeutic efficacy of antiepileptic drugs such as carbamazepine (CBZ). CBZ …

Epilepsy is a neurological condition that affects 70 million individuals worldwide. The BBB,
which manages a series of distinctive properties that safely control the transit of chemicals …

Epilepsy, a condition characterized by unprovoked, recurrent seizures, currently has no
cure, with treatments ranging from medications to treatment modalities such as antiepileptic …